

Market Announcement

12 March 2024

Painchek Ltd (ASX: PCK) – Trading Halt

Description

The securities of Painchek Ltd ('PCK') will be placed in trading halt at the request of PCK, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 14 March 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

12 March 2024

Ms Lisa Banh
Senior Adviser, Listings Compliance (Sydney)
ASX Compliance Pty Limited
20 Bridge Street, Sydney NSW 2000

Via Email: tradinghaltssydney@asx.com.au;

Painchek Ltd (ASX Code: PCK) - Request for Trading Halt

Painchek Ltd (ACN 146 035 127) (**PCK**) requests that a trading halt be granted by the Australian Securities Exchange (**ASX**) in respect of its securities in accordance with Listing Rule 17.1, effective from commencement of trading today.

For the purposes of ASX Listing Rule 17.1, PCK provides the following information regarding this request:

(a) *Commencement of trading halt:*

PCK requests that the trading halt commence with effect from commencement of trading on Tuesday, 12 March 2024;

(b) *Reason for the trading halt:*

PCK seeks a trading halt pending an announcement regarding a capital raise;

(c) *Duration of trading halt:*

PCK requests that the trading halt continues until the earliest of:

- (1) PCK making an ASX announcement regarding a proposed capital raising;
- (2) before the opening of trading on Thursday, 14 March 2024; or
- (3) PCK separately requests that the trading halt be lifted;

(d) *Event that is expected to end the trading halt:*

An announcement by PCK of the specifics of its intended capital raising (to be made as soon as possible and, in any event, prior to the opening of trading on Thursday, 14 March 2024);

PCK considers that the trading halt is necessary as otherwise trading in PCK's securities would continue on an uninformed basis. PCK is not aware of any reason why a trading halt should not be granted, or any other information necessary to inform the market about the requested trading halt.

This trading halt request has been approved by the Company's Board of Directors.

Yours faithfully,

Natalia Climo

Natalia Climo
Company Secretary

About PainChek

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,000 aged care facilities, with more than 4,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>